Skip to main content
Premium Trial:

Request an Annual Quote

Mathai Mammen

Mathai Mammen has joined the board of directors of 10x Genomics. He is the global head of science and development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to that, he was senior vice president at Merck Research Laboratories, where he led several disease research programs. Before that, he led research and development at Theravance, a company he cofounded. Mammen holds an MD from the Harvard Medical School and Massachusetts Institute of Technology HST program and a PhD in chemistry from Harvard University, as well as a BSc in chemistry and biochemistry from Dalhousie University.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.